ইঙ্গিত ও ব্যবহার
Epirubicin Sandoz এর জন্য নির্দেশিত:
ডোজ নির্দেশিকা
শুধুমাত্র নির্দেশিকা তথ্য
প্রদর্শিত ডোজগুলি সরকারি উৎসের সাধারণ নির্দেশিকা। ব্যক্তিগতকৃত ডোজের জন্য সর্বদা আপনার ডাক্তার বা ফার্মাসিস্টের পরামর্শ নিন।
Adults:
Where possible, to lower the risk of cardiotoxicity in patients who start Epirubicin after stopping other cardiotoxic agents, especially those with long half-lives such as Trastuzumab, Epirubicin-based therapy should be delayed until those agents have cleared from the circulation. Epirubicin Injection should be given by intravenous infusion. Epirubicin is given in repeated cycles of 3 to 4 weeks. The total dose of Epirubicin may be given on day 1 of each cycle, or divided equally and given on days 1 and 8 of each cycle. The recommended dose of Epirubicin is 100 to 120 mg/m². The following regimens are recommended. CEF-120: Cyclophosphamide 75 mg/m² orally on days 1 to 14, Epirubicin 60 mg/m² intravenously on days 1 and 8, and 5-Fluorouracil 500 mg/m² intravenously on days 1 and 8, repeated every 28 days for 6 cycles. FEC-100: 5-Fluorouracil 500 mg/m², Epirubicin 100 mg/m² and Cyclophosphamide 500 mg/m², with all drugs given intravenously on day 1 and repeated every 21 days for 6 cycles. Patients receiving the 120 mg/m² regimen of Epirubicin should be given prophylactic antibiotic therapy. Or, as directed by the registered physician.
পার্শ্বপ্রতিক্রিয়া
The most commonly reported side effects are myelosuppression, cardiotoxicity, hair loss, very high fever, lethargy, absence of menstrual periods, nausea, vomiting, diarrhoea, fever, rash, loss of appetite, and a harmless reddish colour of the urine for 1 to 2 days.
সতর্কতা ও নিষেধাজ্ঞা
Warnings & Precautions
Storing the solution for injection in a refrigerator can cause it to form a gel. This gelled product returns to a slightly viscous or free-flowing solution after 2 to 4 hours at controlled room temperature (15°C to 25°C). Before giving any injectable medicine, check it by eye for particles and discolouration whenever the solution and container allow. Follow the correct procedures for handling and disposing of anticancer drugs when handling and preparing Epirubicin Sandoz. Epirubicin Sandoz Injection should be given only under the supervision of qualified doctors with experience in cytotoxic therapy. Before starting treatment with Epirubicin Sandoz, patients should have recovered from the acute toxicities of any previous cytotoxic treatment, such as stomatitis, neutropenia, thrombocytopenia and generalised infections. The first course of Epirubicin Sandoz should also be preceded by a careful baseline assessment of blood counts, serum levels of total bilirubin, AST and creatinine, and cardiac function as measured by left ventricular ejection fraction (LVEF). Patients should be watched closely during treatment for clinical complications caused by myelosuppression. Supportive care may be needed to treat severe neutropenia and serious infections. Monitoring for possible cardiotoxicity is also important, particularly as the cumulative dose of Epirubicin Sandoz increases.
নিষেধাজ্ঞা
Epirubicin must not be given to anyone with a known hypersensitivity to Epirubicin, to other anthracyclines or anthracenediones, or to any other ingredient of this product.